New perspectives and interdisciplinary insights on the benefits of MR antagonism in CKD and T2D

Chair: Paola Fioretto (ITA)

18:30  –18:35

Welcome and introductions

Paola Fioretto (ITA)

18:35 – 18:45

Addressing unmet needs in CKD and T2D with nonsteroidal MR antagonists

Roland Schmieder (GER)

18:45 – 19:00

MR antagonism confers benefits irrespective of anti-diabetic agents or metabolic status: Insights from FIDELIO-DKD

Paola Fioretto (ITA)

19:00 – 19:15

FIGARO-DKD: Expanding the benefit of MR antagonism in CKD and T2D

Samy Hadjadj (FRA)

19:15 – 19:25

Q&A

All faculty

19:25 – 19:30

Summary and close

Paola Fioretto (ITA)